Cambridge-based startup Lila Sciences has emerged from two years of stealth mode, announcing it has raised $200 million to pursue its goal of achieving 'scientific superintelligence.' The company claims its AI technology can revolutionize scientific discovery at unprecedented speeds, with plans to design and execute trials with human assistance guided by AI. This ambitious initiative reflects a growing trend in the biotechnology sector, where AI is increasingly seen as a catalyst for accelerating drug discovery and addressing complex diseases. Industry experts emphasize the transformative potential of AI in materials science and drug development, highlighting its ability to significantly reduce the time required for research and trials.